Skip to main content
NCBI home page
The British Journal of Cancer. Supplement logoLink to The British Journal of Cancer. Supplement
. 1994 Sep;23:S54–S55.

Monoclonal antibody therapy in Langerhans cell histiocytosis--feasible and reasonable?

K M Kelly 1, J Pritchard 1
PMCID: PMC2149709  PMID: 8075008

Abstract

Many recent studies have demonstrated the range of disorders in which monoclonal antibodies have a clinical role. The monoclonal antibody NA1/34, directed against a surface antigen present on lesional cells ('LCH cells'), has been found to localise in vivo to sites of disease. This review explores the possible applications and limitations of monoclonal antibody based-therapy in Langerhans cell histiocytosis.

Full text

PDF
S54

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Grossbard M. L., Press O. W., Appelbaum F. R., Bernstein I. D., Nadler L. M. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood. 1992 Aug 15;80(4):863–878. [PubMed] [Google Scholar]
  2. Isaacs J. D., Watts R. A., Hazleman B. L., Hale G., Keogan M. T., Cobbold S. P., Waldmann H. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet. 1992 Sep 26;340(8822):748–752. doi: 10.1016/0140-6736(92)92294-p. [DOI] [PubMed] [Google Scholar]
  3. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7;256(5517):495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
  4. Lockwood C. M., Thiru S., Isaacs J. D., Hale G., Waldmann H. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet. 1993 Jun 26;341(8861):1620–1622. doi: 10.1016/0140-6736(93)90759-a. [DOI] [PubMed] [Google Scholar]
  5. Mathieson P. W., Cobbold S. P., Hale G., Clark M. R., Oliveira D. B., Lockwood C. M., Waldmann H. Monoclonal-antibody therapy in systemic vasculitis. N Engl J Med. 1990 Jul 26;323(4):250–254. doi: 10.1056/NEJM199007263230407. [DOI] [PubMed] [Google Scholar]
  6. McLelland J., Pritchard J., Chu A. C. Current controversies. Histiocytosis-X. Hematol Oncol Clin North Am. 1987 Mar;1(1):147–162. [PubMed] [Google Scholar]
  7. McMichael A. J., Pilch J. R., Galfré G., Mason D. Y., Fabre J. W., Milstein C. A human thymocyte antigen defined by a hybrid myeloma monoclonal antibody. Eur J Immunol. 1979 Mar;9(3):205–210. doi: 10.1002/eji.1830090307. [DOI] [PubMed] [Google Scholar]
  8. Oosterwijk E., Bander N. H., Divgi C. R., Welt S., Wakka J. C., Finn R. D., Carswell E. A., Larson S. M., Warnaar S. O., Fleuren G. J. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol. 1993 Apr;11(4):738–750. doi: 10.1200/JCO.1993.11.4.738. [DOI] [PubMed] [Google Scholar]
  9. Ortaldo J. R., Woodhouse C., Morgan A. C., Herberman R. B., Cheresh D. A., Reisfeld R. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol. 1987 May 15;138(10):3566–3572. [PubMed] [Google Scholar]
  10. Press O. W., Eary J. F., Appelbaum F. R., Martin P. J., Badger C. C., Nelp W. B., Glenn S., Butchko G., Fisher D., Porter B. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993 Oct 21;329(17):1219–1224. doi: 10.1056/NEJM199310213291702. [DOI] [PubMed] [Google Scholar]
  11. Pritchard K. K., Gordon I., Beverley P. C., Chu A. C. CD1 antibody immunolocalisation in Langerhans' cell histiocytosis. Lancet. 1993 Aug 7;342(8867):367–368. doi: 10.1016/0140-6736(93)91510-s. [DOI] [PubMed] [Google Scholar]
  12. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 1988 Mar 24;332(6162):323–327. doi: 10.1038/332323a0. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Cancer. Supplement are provided here courtesy of Cancer Research UK

RESOURCES